Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399(10319):61–116. https://doi.org/10.1016/S0140-6736(21)01701-3. (Epub 2021/12/06)

Article  PubMed  Google Scholar 

Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int 2023;17(5):1082–1097. https://doi.org/10.1007/s12072-023-10568-z. (Epub 20230809)

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77(4):1335–1347. https://doi.org/10.1097/HEP.0000000000000004. (Epub 2023/01/11)

Article  PubMed  Google Scholar 

Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States. J Clin Exp Hepatol 2023;13(3):454–467. https://doi.org/10.1016/j.jceh.2022.12.005. (Epub 2023/05/30)

Article  CAS  PubMed  Google Scholar 

van Meer S, van Erpecum KJ, Sprengers D, Klumpen HJ, Jansen PL, Ijzermans JN, et al. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28(8):955–962. https://doi.org/10.1097/MEG.0000000000000641. (Epub 2016/05/20)

Article  PubMed  Google Scholar 

Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol 2023;58(10):947–964. https://doi.org/10.1007/s00535-023-02021-7. (Epub 20230720)

Article  PubMed  PubMed Central  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039. (Epub 2020/04/12)

Article  PubMed  Google Scholar 

Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2022;52(5):422–432. https://doi.org/10.1111/hepr.13706. (Epub 20210917)

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79(6):1542–1556. https://doi.org/10.1016/j.jhep.2023.06.003. (Epub 20230624)

Article  CAS  PubMed  Google Scholar 

Dao AD, Nguyen VH, Ito T, Cheung R, Nguyen MH. Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. Hepatol Int 2023;17(1):225–236. https://doi.org/10.1007/s12072-022-10436-2. (Epub 20221029)

Article  Google Scholar 

Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2023;21(10):2496-507e5. https://doi.org/10.1016/j.cgh.2022.11.019. (Epub 2022/11/29)

Article  PubMed  Google Scholar 

Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313(22):2263–2273. https://doi.org/10.1001/jama.2015.5370. (Epub 2015/06/10)

Article  CAS  PubMed  Google Scholar 

Gofton C, Clark-Dickson M, George J. Lean metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am 2023;52(3):431–444. https://doi.org/10.1016/j.ecl.2023.02.003. (Epub 20230321)

Article  PubMed  Google Scholar 

Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci 2021;22(8):4156. https://doi.org/10.3390/ijms22084156. (Epub 20210416)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 2021;74(4):2241–2250. https://doi.org/10.1002/hep.32047. (Epub 2021/07/08)

Article  PubMed  Google Scholar 

Vos B, Moreno C, Nagy N, Fery F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74(3):389–394 (Epub 2011/11/23)

PubMed  Google Scholar 

Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol 2023;21(8):1978–1991. https://doi.org/10.1016/j.cgh.2023.04.015. (Epub 2023/05/01)

Article  PubMed  Google Scholar 

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol 2017;15(10):1604–1611. https://doi.org/10.1016/j.cgh.2017.04.045. (Epub 2017/05/31)

Article  PubMed  Google Scholar 

Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27(10):1555–1560. https://doi.org/10.1111/j.1440-1746.2012.07222.x. (Epub 2012/06/30)

Article  PubMed  Google Scholar 

Francque S, Wong VW. NAFLD in lean individuals: not a benign disease. Gut 2022;71(2):234–236. https://doi.org/10.1136/gutjnl-2021-324162. (Epub 20210312)

Article  Google Scholar 

Ramírez-Mejía MM, Qi X, Abenavoli L, Romero-Gómez M, Eslam M, Méndez-Sánchez N. Metabolic dysfunction: the silenced connection with fatty liver disease. Ann Hepatol 2023;28(6):101138. https://doi.org/10.1016/j.aohep.2023.101138. (Epub 20230717)

Article  CAS  PubMed  Google Scholar 

Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis 2019;39(1):86–95. https://doi.org/10.1055/s-0038-1677517. (Epub 20190117)

Article  CAS  PubMed  Google Scholar 

Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, et al. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22(2):351–366. https://doi.org/10.1007/s11154-020-09621-1. (Epub 20210103)

Article  PubMed Central  Google Scholar 

Ramírez-Mejía MM, Méndez-Sánchez N. What is in a name: from NAFLD to MAFLD and MASLD—unraveling the complexities and implications. Curr Hepatol Rep 2023. https://doi.org/10.1007/s11901-023-00620-9

Article  Google Scholar 

Duseja A, De A, Wong V. Special population: lean nonalcoholic fatty liver disease. Clin Liver Dis 2023;27(2):451–469. https://doi.org/10.1016/j.cld.2023.01.011. (Epub 20230226)

Article  Google Scholar 

Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, et al. Nonalcoholic fatty liver disease in the rotterdam study: about muscle mass, sarcopenia, fat mass, and fat distribution. J Bone Miner Res 2019;34(7):1254–1263. https://doi.org/10.1002/jbmr.3713

Article  CAS  Google Scholar 

Bansal S, Vachher M, Arora T, Kumar B, Burman A. Visceral fat: a key mediator of NAFLD development and progression. Hum Nutr Metab 2023;33: 200210. https://doi.org/10.1016/j.hnm.2023.200210

Article  CAS  Google Scholar 

Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int 2019;13(6):674–687. https://doi.org/10.1007/s12072-019-09996-7. (Epub 20191108)

Article  CAS  PubMed  Google Scholar 

Li AA, Kim D, Ahmed A. Association of sarcopenia and NAFLD: an overview. Clin Liver Dis (Hoboken) 2020;16(2):73–76. https://doi.org/10.1002/cld.900. (Epub 20200904)

Article  Google Scholar 

Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol (Lausanne) 2023;14:1217249. https://doi.org/10.3389/fendo.2023.1217249. (Epub 20230623)

Article  PubMed  Google Scholar 

Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation 2022;45(1):31–44. https://doi.org/10.1007/s10753-021-01559-z

Article  CAS